Biologic drugs that target IL-6 were introduced into clinical practice for non-infectious uveitis approximately 10 years ago, and multiple studies have shown beneficial effects in patients; specific therapeutic effects of the standard blocking agent, tocilizumab – which targets IL-6 signaling – include resolution of macular oedema and retinal vasculitis [6–8]. Here, IL6 is linked to retinal vasculitis.